Sacubitril/Valsartan in Daily Clinical Practice: Data From a Prospective Registry

ABACUS/Manakin Repository

Show simple item record

dc.contributor.author Vicent, Lourdes
dc.contributor.author Esteban Fernández, Alberto
dc.contributor.author Gómez Bueno, Manuel
dc.contributor.author Juan, Javier de
dc.contributor.author Díez Villanueva, Pablo
dc.contributor.author Iniesta, Ángel Manuel
dc.contributor.author Ayesta, Ana
dc.contributor.author González Saldivar, Hugo
dc.contributor.author Rojas González, Antonio
dc.contributor.author Bover Freire, Ramón
dc.contributor.author Iglesias, Diego
dc.contributor.author García Aguado, Marcos
dc.contributor.author Perea Egido, Jesus Ángel
dc.contributor.author Martínez Sellés Oliveria Soares, Manuel
dc.date.accessioned 2019-05-12T18:24:11Z
dc.date.available 2019-05-12T18:24:11Z
dc.date.issued 2019
dc.identifier.citation Vicent, L., Esteban-Fernández, A., Gómez-Bueno, M., De-Juan, J., Díez-Villanueva, P., Iniesta, Á. M., ... & Iglesias, D. (2019). Sacubitril/valsartan in daily clinical practice: data from a prospective registry. Journal of Cardiovascular Pharmacology, 73(2), 118-124. https://doi.org/10.1097/FJC.0000000000000641 spa
dc.identifier.issn 0160-2446
dc.identifier.issn 1533-4023
dc.identifier.uri http://hdl.handle.net/11268/7890
dc.description.abstract Sacubitril/valsartan (SV) is a new therapy in heart failure with reduced ejection fraction. Our aim was to determine the efficacy and safety of this drug daily clinical practice. We performed a multicenter registry in 10 hospitals. All patients who started SV from October 2016 to March 2017 on an outpatient basis were included. A total of 427 patients started treatment with SV. Mean follow-up was 7.0 ± 0.1 months. Forty-nine patients (11.5%) discontinued SV, and 12 (2.8%) died. SV discontinuation was associated with higher cardiovascular (hazard ratio 13.22, 95% confidence interval, 6.71-15.73, P < 0.001) and all-cause mortality (hazard ratio 13.51, 95% confidence interval 3.22-56.13, P < 0.001). Symptomatic hypotension occurred in 71 patients (16.6%). Baseline N-terminal pro-B-type natriuretic peptide levels, functional class, and left ventricular ejection fraction improved at the end of follow-up in patients who continued with SV (all P values ≤0.001). This improvement was not significant in patients with SV discontinuation. SV has a good tolerability in patients from daily clinical practice. SV withdrawal in patients with heart failure and reduced ejection fraction was independently associated with increased all-cause mortality. Patients who continued with SV presented an improvement in functional class left ventricular ejection fraction and N-terminal pro-B-type natriuretic peptide levels. spa
dc.description.sponsorship Sin financiación spa
dc.language.iso eng spa
dc.title Sacubitril/Valsartan in Daily Clinical Practice: Data From a Prospective Registry spa
dc.type article spa
dc.description.impact 2.598 JCR (2019) Q2, 62/138 Cardiac & Cardiovascular Systems; Q3, 147/270 Pharmacology & Pharmacy spa
dc.description.impact 0.800 SJR (2019) Q2, 110/362 Cardiology and Cardiovascular Medicine, 112/331 Pharmacology spa
dc.description.impact No data IDR 2019 spa
dc.identifier.doi 10.1097/FJC.0000000000000641
dc.rights.accessRights closedAccess spa
dc.subject.uem Insuficiencia cardíaca spa
dc.subject.uem Terapéutica spa
dc.subject.unesco Enfermedad cardiovascular spa
dc.subject.unesco Tratamiento médico spa
dc.subject.unesco Medicamento
dc.description.filiation UEM spa
dc.peerreviewed Si spa

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record